{"doi":"10.1177/030089161309900333","title":"Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine","abstract":"<jats:p>We describe the case of a woman who has been undergoing treatment for HER2-positive metastatic breast cancer since 2002. She presented liver metastasis at diagnosis in February 2002. Combination therapy with docetaxel and trastuzumab was administered as first-line treatment, and a complete response of the hepatic lesion and a partial response at the breast primary cancer site were achieved. After 6 cycles of therapy, the patient underwent surgical excision of the breast and then received trastuzumab alone until progression, which occurred in March 2010 with the development of a right chest wall lesion. The patient progressed after therapy with trastuzumab emtansine (T-DM1) received as second-line treatment. Subsequently, a combination of lapatinib and capecitabine was started in April 2011. At this writing, the patient is still receiving treatment (24 months) and is showing a long-lasting response with a favorable safety profile.</jats:p>","journal":"Tumori Journal","year":2013,"id":610749,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1570397,"name":"Monica Milano","orcid":null,"position":1,"is_corresponding":false},{"id":436032,"name":"Piera Gargiulo","orcid":"0000-0002-8828-4209","position":2,"is_corresponding":false},{"id":1570398,"name":"Brigida Stanzione","orcid":null,"position":3,"is_corresponding":false},{"id":1570399,"name":"Valeria Forestieri","orcid":null,"position":4,"is_corresponding":false},{"id":1570400,"name":"Rossella Lauria","orcid":null,"position":5,"is_corresponding":false},{"id":1513505,"name":"Matilde Pensabene","orcid":null,"position":6,"is_corresponding":false},{"id":1570401,"name":"Felice D'Arco","orcid":null,"position":7,"is_corresponding":false},{"id":1570402,"name":"Sabino De Placido","orcid":null,"position":8,"is_corresponding":false},{"id":1570403,"name":"Grazia Arpino","orcid":null,"position":9,"is_corresponding":false},{"id":263245,"name":"Carmine De Angelis","orcid":"0000-0003-1158-4630","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.","abstract":"We describe the case of a woman who has been undergoing treatment for HER2-positive metastatic breast cancer since 2002. She presented liver metastasis at diagnosis in February 2002. Combination therapy with docetaxel and trastuzumab was administered as first-line treatment, and a complete response of the hepatic lesion and a partial response at the breast primary cancer site were achieved. After 6 cycles of therapy, the patient underwent surgical excision of the breast and then received trastuzumab alone until progression, which occurred in March 2010 with the development of a right chest wall lesion. The patient progressed after therapy with trastuzumab emtansine (T-DM1) received as second-line treatment. Subsequently, a combination of lapatinib and capecitabine was started in April 2011. At this writing, the patient is still receiving treatment (24 months) and is showing a long-lasting response with a favorable safety profile.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24158083","pmcid":null,"openalex_id":"https://openalex.org/W115230284","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.00883279,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://pubmed.ncbi.nlm.nih.gov/24158083","host_type":"repository"}],"fields_of_study":["HER2/EGFR in Cancer Research","Cancer Treatment and Pharmacology","PI3K/AKT/mTOR signaling in cancer","Ado-Trastuzumab Emtansine","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Biomarkers, Tumor","Breast Neoplasms","Capecitabine","Deoxycytidine","Female","Fluorouracil","Humans","Lapatinib","Maytansine","Middle Aged","Quinazolines","Erb-b2 Receptor Tyrosine Kinases","Time Factors","Trastuzumab","Treatment Outcome","Up-Regulation"],"mesh_terms":["Trastuzumab","Capecitabine","Lapatinib","Ado-Trastuzumab Emtansine","Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms","Deoxycytidine","Female","Fluorouracil","Humans","Maytansine","Middle Aged","Quinazolines","Time Factors","Biomarkers, Tumor","Up-Regulation","Treatment Outcome","Receptor, ErbB-2","Erb-b2 Receptor Tyrosine Kinases","Antibodies, Monoclonal, Humanized"],"keywords":["Capecitabine","Lapatinib","Medicine","Trastuzumab","Trastuzumab emtansine","Metastatic breast cancer","Oncology","Docetaxel","Internal medicine","Breast cancer","Cancer","Metastasis","Surgery","Colorectal cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T11:03:24.798918Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}